BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1493 related articles for article (PubMed ID: 23761549)

  • 41. Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.
    Sasaki M; Tozaki M; Kubota K; Murakami W; Yotsumoto D; Sagara Y; Ohi Y; Oosako S; Sagara Y
    Jpn J Radiol; 2018 Feb; 36(2):122-133. PubMed ID: 29159779
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between tissue metabolism and cellularity assessed by standardized uptake value and apparent diffusion coefficient in peritoneal metastasis.
    Yu X; Lee EY; Lai V; Chan Q
    J Magn Reson Imaging; 2014 Jul; 40(1):99-105. PubMed ID: 24170710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
    Baba S; Isoda T; Maruoka Y; Kitamura Y; Sasaki M; Yoshida T; Honda H
    J Nucl Med; 2014 May; 55(5):736-42. PubMed ID: 24665089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix.
    Olsen JR; Esthappan J; DeWees T; Narra VR; Dehdashti F; Siegel BA; Schwarz JK; Grigsby PW
    J Magn Reson Imaging; 2013 Feb; 37(2):431-4. PubMed ID: 23023940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma.
    Kitajima K; Yamano T; Fukushima K; Miyoshi Y; Hirota S; Kawanaka Y; Miya M; Doi H; Yamakado K; Hirota S
    Eur J Radiol; 2016 May; 85(5):943-9. PubMed ID: 27130054
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
    Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlations between DW-MRI and
    Connor S; Sit C; Anjari M; Szyszko T; Dunn J; Pai I; Cook G; Goh V
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1360. PubMed ID: 33960739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.
    Heijmen L; ter Voert EE; Oyen WJ; Punt CJ; van Spronsen DJ; Heerschap A; de Geus-Oei LF; van Laarhoven HW
    PLoS One; 2015; 10(4):e0120823. PubMed ID: 25831053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
    Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrated PET/MR mammography for quantitative analysis and correlation to prognostic factors of invasive ductal carcinoma.
    Kong E; Chun KA; Bae YK; Cho IH
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):118-126. PubMed ID: 26784940
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.
    Ng SH; Lin CY; Chan SC; Lin YC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Chang CJ; Wang JJ
    PLoS One; 2014; 9(12):e115933. PubMed ID: 25531391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology in Terms of Anatomic Correlation of FDG-positive Lesions.
    Uslu-Beşli L; Atay Kapucu LÖ; Karadeniz C; Akdemir ÜÖ; Pinarli FG; Aydos U; Okur A; Kaya Z; Samanci C; Karabacak NI
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):542-550. PubMed ID: 30933019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ¹⁸F-FDG PET/CT and contrast enhanced CT in differential diagnosis between leiomyoma and gastrointestinal stromal tumor.
    Hirose Y; Kaida H; Kawahara A; Kurata S; Ishibashi M; Abe T
    Hell J Nucl Med; 2015; 18(3):257-60. PubMed ID: 26574696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.
    Afaq A; Fraioli F; Sidhu H; Wan S; Punwani S; Chen SH; Akin O; Linch D; Ardeshna K; Lambert J; Miles K; Groves A; Kayani I
    Clin Nucl Med; 2017 Jan; 42(1):e1-e7. PubMed ID: 27607161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiparametric analysis of bone marrow in cancer patients using simultaneous PET/MR imaging: Correlation of fat fraction, diffusivity, metabolic activity, and anthropometric data.
    Schraml C; Schmid M; Gatidis S; Schmidt H; la Fougère C; Nikolaou K; Schwenzer NF
    J Magn Reson Imaging; 2015 Oct; 42(4):1048-56. PubMed ID: 25683203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.